BTNL8 and COVID-19: To explore the role of BTNL8 in other infectious diseases and to ascertain that the observed differential burden was not due to technical artifacts or methodological limitations, we applied burdenMC directly to two other sequencing cohorts: an in-house WES data from 502 pediatric patients with severe bacterial infections from the EUCLIDS consortium (Martinón-Torres et al., 2018), and 189 patients with COVID-19 from the COVID Human Genetic Effort (COVID-HGE) consortium (Table S1) (Casanova et al., 2020).